Contract Delays Force Genaissance to Cut 2004 Revenue Outlook by 20 Percent

genomeweb
360dx

Contract Delays Force Genaissance to Cut 2004 Revenue Outlook by 20 Percent

Oct 21, 2004

NEW YORK, Oct. 21 (GenomeWeb News) - Genaissance Pharmaceuticals lowered by around 20 percent its year-end revenue expectations, to between $20 million and $21 million from $25 million, the company said today.

To read the full story....

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

Canadian Government, Industry Invest C$21M in Genomic Applications Program
Tecan Acquires NuGen for $54.5M
Exome Sequencing Study Implicates New Breast, Ovarian Cancer Susceptibility Genes
Tufts Medical Center, Collaborators Win $8M NIH Grant to Study NGS in Newborns
CoreBiome Awarded $220K Translational Product Development Grant
Genetic Technologies Announces Planned Chinese Joint Venture

The Scan

The Fall of the Yellow-Banded Bumblebee

York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.

If It Is to Help

In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.

Bunch at Once

The Scientist reports agricultural researchers are working on a gene-stacking tool.

This Week in Nature

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.

Main menu